PT-141
Bremelanotide
Overview
PT-141 (Bremelanotide) is a melanocortin receptor agonist originally developed from Melanotan II research. Unlike PDE5 inhibitors that work on blood flow, PT-141 acts directly on the nervous system to enhance sexual desire. It is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Mechanism of Action
PT-141 activates melanocortin-4 receptors (MC4R) in the central nervous system, particularly in the hypothalamus. This activation triggers neural pathways involved in sexual arousal and desire. Unlike vascular-based approaches, it operates through the dopaminergic reward pathways, affecting motivation and desire rather than just physical response.
Dosage Information
Typical Dose
1.75 mg
Frequency
As needed, at least 45 minutes before activity
Administration
Subcutaneous injection
Notes
FDA-approved dose is 1.75mg. Do not use more than once within 24 hours or more than 8 times per month. Onset typically 45-60 minutes. Nausea is common on first use.
Potential Side Effects
Research References
Community Experiences
No experiences shared yet. Be the first!
Stacking Compatibility
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 1.75 mg
- Frequency
- As needed, at least 45 minutes before activity
- References
- 2 studies